| Unexposed, age-matched control patients | ||||
| TSpot positive | TSpot negative | OR | Univariate p | |
| n=13 | n=135 | |||
| n (%) | n (%) | |||
| Age (years), median (range) | 64 (45–87) | 70 (25–93) | 0.81 | |
| Male, n (%) | 5 (38) | 70 (52) | 0.36 | |
| Ethnicity, n (%) | ||||
| White Caucasian | 13 (100) | 135 (100) | ||
| Country of birth | ||||
| UK born | 9 (69) | 125 (93) | 0.18 | 0.006 |
| Other | 4 (31)* | 9 (6.7) | ||
| Years since immigration, median (range) | 43 (21–62) | 52 (8–61) | ||
| Ever visited a high prevalence country, n (%) | 4 (31) | 46 (37) | 0.84 | |
| Years since last visit, median (range) | 8.5 (0–40) | 5.5 (0–60) | ||
| Ever resident in a high prevalence area >6/52, n (%) | 2 (15) | 27 (20) | 0.64 | |
| Occupation: healthcare, prison, lab n (%)† | 4 (31) | 18 (13) | 0.09 | |
| BCG (history or scar), n (%) | ||||
| Yes | 7 (54) | 66 (49) | 0.73 | |
| No | 4 (31) | 44 (33) | ||
| Unknown | 2 (15) | 25 (19) | ||
| Medical history, n (%) | ||||
| Comorbidity known to be associated with TB‡ | 0 (0) | 21 (16) | 0.22 | |
| Immunosuppresive medications§ | 4 (31) | 12 (9.2) | 4.6 | 0.015 |
| Ever known to be exposed to TB | 4 (31) | 26 (19) | 0.32 | |
| Ever had treatment for tuberculosis | 2 (15) | 2 (1.5) | 12 | 0.003 |
↵* Germany (2), South Africa (1), Hong Kong (1).
↵† Percentages are those of those with valid data (eg occupation).
↵‡ Diabetes mellitus (17), chronic renal failure (3), haematological malignancy (2), gastric surgery (1).
↵§ Systemic steroids (12), methotrexate (4), hydroxychloroquine (2), anti-TNF-α (2), sulfasalzine (1).